155 related articles for article (PubMed ID: 24212615)
1. Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation.
Peng CA; Wang CH
Cancers (Basel); 2011 Jan; 3(1):227-40. PubMed ID: 24212615
[TBL] [Abstract][Full Text] [Related]
2. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
3. Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin.
Inagaki FF; Kato T; Furusawa A; Okada R; Wakiyama H; Furumoto H; Okuyama S; Choyke PL; Kobayashi H
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297471
[TBL] [Abstract][Full Text] [Related]
4. Development of chitosan oligosaccharide-modified gold nanorods for in vivo targeted delivery and noninvasive imaging by NIR irradiation.
Charan S; Sanjiv K; Singh N; Chien FC; Chen YF; Nergui NN; Huang SH; Kuo CW; Lee TC; Chen P
Bioconjug Chem; 2012 Nov; 23(11):2173-82. PubMed ID: 23030814
[TBL] [Abstract][Full Text] [Related]
5. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
7. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
[TBL] [Abstract][Full Text] [Related]
8. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Wellens LM; Deken MM; Sier CFM; Johnson HR; de la Jara Ortiz F; Bhairosingh SS; Houvast RD; Kholosy WM; Baart VM; Pieters AMMJ; de Krijger RR; Molenaar JJ; Wehrens EJ; Dekkers JF; Wijnen MHWA; Vahrmeijer AL; Rios AC
Sci Rep; 2020 Oct; 10(1):17667. PubMed ID: 33077751
[TBL] [Abstract][Full Text] [Related]
9. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of neuroblastomas using GD2-targeting graphene quantum dots.
Lin YS; Chen Y; Tsai YH; Tseng SH; Lin KS
J Pediatr Surg; 2021 Jul; 56(7):1227-1232. PubMed ID: 33838896
[TBL] [Abstract][Full Text] [Related]
11. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
[TBL] [Abstract][Full Text] [Related]
13. Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma.
Privitera L; Waterhouse DJ; Preziosi A; Paraboschi I; Ogunlade O; Da Pieve C; Barisa M; Ogunbiyi O; Weitsman G; Hutchinson JC; Cross K; Biassoni L; Stoyanov D; Sebire N; Beard P; De Coppi P; Kramer-Marek G; Anderson J; Giuliani S
Cancer Res; 2023 Jun; 83(12):2077-2089. PubMed ID: 36934744
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
Castel V; Segura V; Cañete A
Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method.
Adrian JE; Wolf A; Steinbach A; Rössler J; Süss R
Pharm Res; 2011 Sep; 28(9):2261-72. PubMed ID: 21594716
[TBL] [Abstract][Full Text] [Related]
17. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
18. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Monterrubio C; Paco S; Olaciregui NG; Pascual-Pasto G; Vila-Ubach M; Cuadrado-Vilanova M; Ferrandiz MM; Castillo-Ecija H; Glisoni R; Kuplennik N; Jungbluth A; de Torres C; Lavarino C; Cheung NKV; Mora J; Sosnik A; Carcaboso AM
J Control Release; 2017 Jun; 255():108-119. PubMed ID: 28412222
[TBL] [Abstract][Full Text] [Related]
19. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods.
Huang X; El-Sayed IH; Qian W; El-Sayed MA
J Am Chem Soc; 2006 Feb; 128(6):2115-20. PubMed ID: 16464114
[TBL] [Abstract][Full Text] [Related]
20. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
